| First Author | Murakami Y | Year | 2024 |
| Journal | Mol Ther Methods Clin Dev | Volume | 32 |
| Issue | 1 | Pages | 101176 |
| PubMed ID | 38225934 | Mgi Jnum | J:346523 |
| Mgi Id | MGI:7616663 | Doi | 10.1016/j.omtm.2023.101176 |
| Citation | Murakami Y, et al. (2024) AAV-based gene therapy ameliorated CNS-specific GPI defect in mouse models. Mol Ther Methods Clin Dev 32(1):101176 |
| abstractText | Thirty genes are involved in the biosynthesis and modification of glycosylphosphatidylinositol (GPI)-anchored proteins, and defects in these genes cause inherited GPI deficiency (IGD). PIGA is X-linked and involved in the first step of GPI biosynthesis, and only males are affected by variations in this gene. The main symptoms of IGD are neurological abnormalities, such as developmental delay and seizures. There is no effective treatment at present. We crossed Nestin-Cre mice with Piga-floxed mice to generate CNS-specific Piga knockout (KO) mice. Hemizygous KO male mice died by P10 with severely defective growth. Heterozygous Piga KO female mice are mosaic for Piga expression and showed severe defects in growth and myelination and died by P25. Using these mouse models, we evaluated the effect of gene replacement therapy with adeno-associated virus (AAV). It expressed efficacy within 6 days, and the survival of male mice was extended to up to 3 weeks, whereas 40% of female mice survived for approximately 1 year and the growth defect was improved. However, liver cancer developed in all three treated female mice at 1 year of age, which was probably caused by the AAV vector bearing a strong CAG promoter. |
